Skip to main content
SpringerLink
Log in

In vitro comparative study of drug loading and delivery properties of bioresorbable microspheres and LC bead

  • Delivery Systems
  • Original Research
  • Published:
Journal of Materials Science: Materials in Medicine Aims and scope Submit manuscript

Abstract

Drug loadable bioresorbable microspheres (BRMS) are specially designed for the treatment of hypervascular tumors through arterial embolization. These microspheres consist of carboxymethyl chitosan crosslinked with carboxymethyl cellulose, and are available at different size ranges varying from 50 to 900 µm in diameter. Similar to commercially available non-resorbable drug eluting microspheres, LC Bead® microspheres (LCB), BRMS were capable of loading more than 99 % of doxorubicin, an anticancer drug, from the solution within 2 h with highly similar kinetics (difference factor f 1 = 0.36; similarity factor f 2 = 97.99). Doxorubicin loaded BRMS exhibited the highest elution rate in the 30 % ethanol aqueous solution saturated with potassium chloride, and the elution time depended on the ratio between the amount of loaded BRMS and the volume of elution media. After injection through microcatheters, BRMS have a higher recovery rate of the microsphere weight than LCB (90.96 vs. 79.63 %, P = 0.026). Although loaded BRMS eluted more drug into the injection medium than loaded LCB (8.63 vs. 3.80 %, P = 0.0015), there was no significant difference in the drug delivery rate between BRMS and LCB (83.88 vs. 86.65 %, P = 0.504). This study compares the loading capability as well as the drug delivery rate of BRMS and a commercial product under a condition simulating a transcatheter arterial chemoembolization procedure and demonstrates the potential of drug loaded BRMS for the treatment of hypervascular tumors such as hepatocellular carcinoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:359–86.

    Article  Google Scholar 

  2. Jiang L, Lei JY, Wang WT, Yan LN, Li B, Wen TF, et al. Immediate radical therapy or conservative treatments when meeting the milan criteria for advanced HCC patients after successful TACE. J Gastrointest Surg. 2014;18(6):1125–30.

    Article  Google Scholar 

  3. Yammasaki T, Hamabe S, Saeki I, Harima Y, Yamaguchi Y, Uchida K, et al. A novel transarterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial. J Gastroenterol. 2011;46:359–66.

    Article  Google Scholar 

  4. Singal AG, Zhang P, Waljee AK, Ananthakrishnan L, Parikh ND, Sharma P, et al. Body composition features predict overall survival in patients with hepatocellular carcinoma. Clin Trans Gastroenterol. 2016;26(7):e172.

    Article  Google Scholar 

  5. Grandhi MS, Kim AK, Ronnekleiv-Kelly SM, Kamel IR, Ghasebeh MA, Pawlik TM. Hepatocellular carcinoma: from diagnosis to treatment. Surg Oncol. 2016;25:74–85.

    Article  Google Scholar 

  6. Sperker B, Murdter TE, Schick M, Eckhardt K, Bosslet K, Kroemer HK. Interindividual variability in expression and activity of human β-glucuronidase in liver and kidney: consequences for drug metabolism. J Pharmacol Exp Ther. 1997;281:914–20.

    Google Scholar 

  7. Llovet JM, Real MI, Montanya X, Planas R, Coll S, Aponte J, et al. Arterial embolization, chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet. 2002;359:1734–9.

    Article  Google Scholar 

  8. Tsurusaki M, Murakami T. Surgical and locoregional therapy of HCC: TACE. Liver Cancer. 2015;4(3):165–75.

    Article  Google Scholar 

  9. Lewis AL, Gonzalez MV, Lloyd AW, Hall B, Tang Y, Willis SL, et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. J Vasc Interv Radiol. 2006;17:335–42.

    Article  Google Scholar 

  10. Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF. New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res. 2006;12:2563–7.

    Article  Google Scholar 

  11. Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474–81.

    Article  Google Scholar 

  12. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33:41–52.

    Article  Google Scholar 

  13. Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniotou A, et al. Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol. 2012;35:1119–28.

    Article  Google Scholar 

  14. Malagari K, Alexopoulou E, Chatzimichail K, Hall B, Koskinas J, Ryan S, et al. Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin loaded DC bead. Abdom Imaging. 2008;33:512–9.

    Article  Google Scholar 

  15. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC). J Surg Oncol. 2010;101:476–80.

    Google Scholar 

  16. Jordan O, Denys A, De Baere T, Boulens N, Doelker E. Comparative study of chemoembolization loadable beads: in vitro drug release and physical properties of DC bead and hepasphere loaded with doxorubicin and irinotecan. J Vasc Interv Radiol. 2010;21:1084–90.

    Article  Google Scholar 

  17. Weng L, Rostamzadeh P, Nooryshokry N, Le HC, Golzarian J. In vitro and in vivo evaluation of biodegradable embolic microspheres with tunable anticancer drug release. Acta Biomaterialia. 2013;9:6823–33.

    Article  Google Scholar 

  18. Weng L, Seelig D, Rostamzadeh P, Golzarian J. Calibrated bioresorbable microspheres as an embolic agent: an experimental study in a rabbit renal model. J Vasc Interv Radiol. 2015;26(12):1887–94.

    Article  Google Scholar 

  19. Weng L, Le H, Lin J, Golzarian J. Doxorubicin loading and eluting characteristics of bioresorbable hydrogel microspheres: in vitro study. Int J Pharm. 2011;409:185–93.

    Article  Google Scholar 

  20. Lewis AL, Gonzalez MV, Leppard SW, Brown JE, Stratford PW, Phillips GJ, et al. Doxorubicin eluting beads - 1: effects of drug loading on bead characteristics and drug distribution. J Mater Sci Mater Med. 2007;18(9):1691–9.

    Article  Google Scholar 

  21. Gonzalez MV, Tang Y, Phillips GJ, Lloyd AW, Hall B, Stratford PW, et al. Doxorubicin eluting beads—2: methods for evaluating drug elution and in-vitro:in-vivo correlation. J Mater Sci: Mater Med. 2008;19:767–75.

    Google Scholar 

  22. U.S. Food and Drug Administration. Guidance for industry CMC5-1995: immediate release solid oral dosage forms. Published November 1995. Updated August 1, 1997. Accessed December 13, 2015.

  23. Weng L, Le HC, Talaie R, Golzarian J. Bioresorbable hydrogel microspheres for transcatheter embolization: Preparation and in vitro evaluation. J Vasc Interv Radiol. 2011;22:1464–70.

  24. Poursaid A, Jensen MM, Huo E, Ghandehari H. Polymeric materials for embolic and chemoembolic applications. J Control Release 2016, in press.

  25. Yuan J, Gao Y, Wang X, Liu H, Che X, Xu L, et al. The load and release characteristics on a strong cationic ion-exchange fiber: kinetics, thermodynamics, and influences. Drug Des Devel Ther. 2014;16(8):945–55.

    Google Scholar 

  26. Biondi M, Fusco S, Lewis A, Netti P. New insights into the mechanisms of the interactions between doxorubicin and the ion-exchange hydrogel LC Bead™ for use in transarterial chemoembolization (TACE). J Biomater Sci Polym Ed. 2012;23:333–54.

    Article  Google Scholar 

  27. Arabi M, BenMousa A, Bzeizi K, Garad F, Ahmed I, Al-Otaibi M. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma. Saudi J Gastroenterol. 2015;21(3):175–80.

    Article  Google Scholar 

  28. Kim JO, Kabanov AV, Bronich TK. Polymer micelles with cross-linked polyanion core for delivery of a cationic drug doxorubicin. J Control Release. 2009;138(3):197–204. 15

    Article  Google Scholar 

  29. Kitaeva MV, Melik-Nubarov NS, Menger FM, Yaroslavov AA. Doxorubicin-poly(acrylic acid) complexes: interaction with liposomes. Langmuir. 2004;20:6575–9.

    Article  Google Scholar 

  30. Zhou X, Kong M, Cheng XJ, Feng C, Li J, Li JJ, et al. In vitro and in vivo evaluation of chitosan microspheres with different deacetylation degree as potential embolic agent. Carbohydr Polym. 2014;113:304–13.

    Article  Google Scholar 

  31. Unsoy G, Khodadust R, Yalcin S, Mutlu P, Gunduz U. Synthesis of doxorubicin loaded magnetic chitosan nanoparticles for pH responsive targeted drug delivery. Eur J Pharm Sci. 2014;62:243–50.

    Article  Google Scholar 

  32. Macchiarulo A, Pellicciari R. Exploring the other side of biological relevant chemical space: insight into carboxylic, sulfonic and phosphonic acid bioisosteric relationship. J Mol Graph Model. 2007;26:728–39.

    Article  Google Scholar 

Download references

Acknowledgments

This is study was partially supported by a RSNA medical student grant (2012, Tseng).

Author information

Authors and Affiliations

  1. Department of Radiology, University of Minnesota, 420 Delaware St SE, Minneapolis, MN, 55455, USA

    Lihui Weng, Hsiang-Jer Tseng, Parinaz Rostamzadeh & Jafar Golzarian

Authors
  1. Lihui Weng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hsiang-Jer Tseng
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Parinaz Rostamzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jafar Golzarian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jafar Golzarian.

Ethics declarations

Conflict of interest

Lihui Weng and Jafar Golzarian hold a patent on the BRMS, and they are the chief scientist officer and chief medical officer of Embomedics Inc which licensed the BRMS technology from University of Minnesota. The authors declare that they have no conflict of interest.

Electronic supplementary material

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Weng, L., Tseng, HJ., Rostamzadeh, P. et al. In vitro comparative study of drug loading and delivery properties of bioresorbable microspheres and LC bead. J Mater Sci: Mater Med 27, 174 (2016). https://doi.org/10.1007/s10856-016-5786-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10856-016-5786-2

Keywords

Search

Navigation